A case of successful treatment of cutaneous Acanthamoeba infection in a lung transplant recipient.
Acanthamoeba species are known to cause 2 well-described entities: (1) granulomatous amoebic encephalitis (GAE), which usually affects immunocompromised hosts, and (2) keratitis, which typically follows trauma associated with contamination of water or contact lenses. Less common manifestations include pneumonitis and a subacute granulomatous dermatitis. We describe a case of granulomatous dermatitis secondary to Acanthamoeba infection in a lung transplant recipient and a successful outcome following treatment with lipid formulation of amphotericin B and voriconazole. We believe this is the second case report describing disseminated Acanthamoeba infection in a lung transplant recipient. We also describe successful outcome with a combination of lipid formulation of amphotericin B and voriconazole, drugs that have not been previously reported to treat Acanthamoeba.
Walia
R
R
Pulmonary and Critical Care, University of Florida, Gainesville, FL 32610-0225, USA.
Montoya
J G
JG
Visvesvera
G S
GS
Booton
G C
GC
Doyle
R L
RL
D000048:Acanthamoeba; D000208:Acute Disease; D000562:Amebiasis / Q000188:drug therapy* / Q000209:etiology*; D000666:Amphotericin B / Q000008:administration & dosage*; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D002626:Chemistry, Pharmaceutical; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008055:Lipids / Q000008:administration & dosage; D016040:Lung Transplantation / Q000009:adverse effects*; D008875:Middle Aged; D011183:Postoperative Complications / Q000628:therapy*; D011743:Pyrimidines / Q000008:administration & dosage*; D012876:Skin Diseases, Parasitic / Q000209:etiology* / Q000628:therapy*; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage*; D065819:Voriconazole
D000981:Antiprotozoal Agents; D008055:Lipids; D011743:Pyrimidines; D014230:Triazoles; D000666:Amphotericin B; D065819:Voriconazole